Novartis halts early lymphoma drug trial
NCT ID NCT04903197
Summary
This early-stage study aimed to find a safe dose of the experimental drug VAY736, given alone or with other cancer drugs, for adults with several types of Non-Hodgkin Lymphoma that had returned or stopped responding to standard treatments. The main goal was to check for side effects and determine the best dose to use. The company stopped the trial early for business reasons, not because of safety problems, so the full testing plan was not completed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA, DIFFUSE LARGE B CELL LYMPHOMA, FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Leipzig, 04103, Germany
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Yamagata, 990 9585, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
Conditions
Explore the condition pages connected to this study.